The crux of the matter [to me] is the presentation of PV-10 as a systemic agent. The brass ring is the large market for melanoma. The more lustrous brass ring is the use of PV-10 for the systemic treatment of [lots of] other cancer indications.
That is what makes the murine study results from Moffitt potentially extremely interesting. In their first release of information, Moffitt identified the quintessential immune response for melanoma, confirming PV-10's very beneficial/positive systemic impact. It has been widely speculated the next release could contain comparable success and confirmation for several other cancer indications.
Recall Koevary's work on rose bengal for ovarian cancer.
Clinical trials, the compassionate use program, Moffitt, Koevary, etc. clearly point to the broad application of PV-10 to effectively and safely treat all sorts of cancers.
It is very notable how much the dialog about PV-10 has changed within the medical and scientific community.
I learned (from speaking to someone, who kindly shared his due diligence on Provectus) that several surgeons conceived of a thoughtful, potential diagnostic/treatment approach for PV-10 and patients of theirs afflicted with breast cancer.
These surgical oncologists would use PV-10, when the appropriate time comes, as a pre-surgery diagnostic tool to precisely highlight cancerous regions or areas in a breast and a post-surgery diagnostic to precisely highlight cancerous locations (if any) potentially missed by surgery. PV-10 of course would also be used to treat breast cancer, as part of the physcian's decision tree.
This information in many respects closes the loop for me about past discussions I had with Craig where he raged against the destruction of breast tissue in search of ways or means to beat breast cancer and women's emotional pain and identity loss of losing such breast material (my mother is a two-time breast cancer survivor). Craig also shared his thoughts on how PV-10 could be effectively used to reduce or minimize unnecessary tissue removal (and, thus, emotional hurt).
This is but one example of how the dialog has changed about PV-10, elevating the dialog from the drug's novelty or novel features to how PV-10 can be used as productively as possible to eradicate cancer.